Tap, William D <br/><br/>
Phase II study of ganitumab, a fully human anti-type-1 insulin-like growth factor receptor antibody, in patients with metastatic Ewing family tumors or desmoplastic small round cell tumors.  [electronic resource] 

 -  Journal of clinical oncology : official journal of the American Society of Clinical Oncology  May 2012 
 - 1849-56 p.  digital 
<br/><br/> Publication Type: Clinical Trial, Phase II; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't 
<br/><br/><label>ISSN: </label>1527-7755 
<br/><br/><label>Standard No.: </label>10.1200/JCO.2011.37.2359  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Adult<br/>Aged<br/>Antibodies, Monoclonal--adverse effects<br/>Antibodies, Monoclonal, Humanized<br/>Bone Neoplasms--blood<br/>Desmoplastic Small Round Cell Tumor--blood<br/>Female<br/>Humans<br/>In Situ Hybridization, Fluorescence<br/>Insulin-Like Growth Factor I--metabolism<br/>Kaplan-Meier Estimate<br/>Male<br/>Middle Aged<br/>Oncogene Proteins, Fusion--genetics<br/>Proto-Oncogene Protein c-fli-1--genetics<br/>RNA-Binding Protein EWS--genetics<br/>Receptor, IGF Type 1--antagonists & inhibitors<br/>Sarcoma, Ewing--blood<br/>Sequence Analysis, RNA<br/>Time Factors<br/>Translocation, Genetic<br/>Treatment Outcome<br/>Young Adult